Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Rolls Out AI Tool to Guide “Next Best Action” in Sales
June 6, 2025
-
ORGANIZATION New FPMAJ Chair Pushes Category-Based Drug Pricing to Ensure Innovation, Stable Supply
June 5, 2025
-
REGULATORY Early Honebuto Draft Contains CEA Expansion, Ramp-Up of FIH Trial Sites
June 4, 2025
-
ORGANIZATION New JPMA Chief Calls for Clear-Cut Evaluation of Innovation in FY2026 Reform
June 3, 2025
-
REGULATORY New Skipper of PMDA’s Review Center Wears Multiple Hats to Push Fight against Drug Loss
June 2, 2025
-
BUSINESS Taking on Solid Tumors - 3: J&J to Soon Have 3 Bispecifics in Japan as Rybrevant Gathers Pace
May 30, 2025
-
BUSINESS Towa, Sawai Log Two-Digit Growth in Operating Profit, but Industry Sees Divide: Tally
May 30, 2025
-
BUSINESS Taking on Solid Tumors - 2: Chugai Poised to Break through Solid Cancer “Wall” with Trispecific Antibodies
May 29, 2025
-
REGULATORY LDP Pharma Study Group’s Final Proposal Urges Raising of Social Security Budget Ceiling
May 29, 2025
-
REGULATORY LDP Fiscal Reform HQ’s Proposal Keeps Budget Ceiling Intact, but Urges Action on Wage Front
May 28, 2025
-
REGULATORY MOF Panel Again Presses for Expansion of CEA Scheme: “Spring” Proposal
May 27, 2025
-
REGULATORY Honebuto Outline Includes “Raise in Official Prices,” but Details Yet Unknown
May 27, 2025
-
COMMENTARY Next Wave of ALS Drugs Emerging as Novartis, Nipro Enter Development Fray
May 27, 2025
-
BUSINESS Sun Pharma Japan Eyes 10%-Plus CAGR as It Pivots to New Drug Biz
May 26, 2025
-
BUSINESS Novartis Keen to Ensure Stable Supply of Radioligand Therapies in Japan
May 26, 2025
-
ORGANIZATION FPMAJ Sets Out on New Lobbying Push with Astellas’ Yasukawa as New Chief
May 23, 2025
-
ORGANIZATION Takeda’s Miyabashira Elected as New JPMA President
May 23, 2025
-
BUSINESS Japan Pharma Market Grows 1% to Record 11.4 Trillion Yen in FY2024: IQVIA
May 23, 2025
-
BUSINESS MSD Chief Decries Japan’s Unpredictable Policy Flip, Frets Future Investment
May 22, 2025
-
BUSINESS Sanofi Japan Seeing Improved Customer Satisfaction with AI-Powered Sales Support Tool
May 21, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…